No Data
Vazyme Biotech Ties Up With BGI Genomics to Develop Genetic Products
Is BGI Genomics (SZSE:300676) A Risky Investment?
Soochow: AI Medical is accelerating its penetration, with the imaging market size expected to exceed 13.7 billion yuan by 2030.
Although AI health management is still in its early stages of development, it encompasses many subfields and is supported by policies. The market concentration is low, and the competitive landscape is unstable, with demand expected to expand rapidly in the future.
CH BIOTECH SER (08037.HK) signed a Global Strategy cooperation framework agreement with Shenzhen BGI Genomics.
On February 25, Gelonghui announced that CH BIOTECH SER (08037.HK) entered into a strategic cooperation framework agreement with BGI Genomics on February 25, 2025; and (ii) Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. ("Pengbo (Hainan)") (a wholly-owned subsidiary of the company) has signed a letter of intent for investment with Shenzhen BGI Songhe Biotechnology Fund No. 1 Private Equity Venture Capital Partnership (Limited Partnership) ("Investor"), regarding the investment that the investor intends to make in Pengbo (Hainan). BGI and the company in tumor precision.
BGI Genomics Co., Ltd.'s (SZSE:300676) Shares Lagging The Industry But So Is The Business
BGI: 2024 Annual Results Forecast
